Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome
Jason R. Cook, Luca Carta, Ludovic Bénard, Elie R. Chemaly, Emily Chiu, Satish K. Rao, Thomas G. Hampton, Peter Yurchenco, GenTAC Registry Consortium, Kevin D. Costa, Roger J. Hajjar, Francesco Ramirez
Jason R. Cook, Luca Carta, Ludovic Bénard, Elie R. Chemaly, Emily Chiu, Satish K. Rao, Thomas G. Hampton, Peter Yurchenco, GenTAC Registry Consortium, Kevin D. Costa, Roger J. Hajjar, Francesco Ramirez
View: Text | PDF
Research Article Cardiology

Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome

  • Text
  • PDF
Abstract

Patients with Marfan syndrome (MFS), a multisystem disorder caused by mutations in the gene encoding the extracellular matrix (ECM) protein fibrillin 1, are unusually vulnerable to stress-induced cardiac dysfunction. The prevailing view is that MFS-associated cardiac dysfunction is the result of aortic and/or valvular disease. Here, we determined that dilated cardiomyopathy (DCM) in fibrillin 1–deficient mice is a primary manifestation resulting from ECM-induced abnormal mechanosignaling by cardiomyocytes. MFS mice displayed spontaneous emergence of an enlarged and dysfunctional heart, altered physical properties of myocardial tissue, and biochemical evidence of chronic mechanical stress, including increased angiotensin II type I receptor (AT1R) signaling and abated focal adhesion kinase (FAK) activity. Partial fibrillin 1 gene inactivation in cardiomyocytes was sufficient to precipitate DCM in otherwise phenotypically normal mice. Consistent with abnormal mechanosignaling, normal cardiac size and function were restored in MFS mice treated with an AT1R antagonist and in MFS mice lacking AT1R or β-arrestin 2, but not in MFS mice treated with an angiotensin-converting enzyme inhibitor or lacking angiotensinogen. Conversely, DCM associated with abnormal AT1R and FAK signaling was the sole abnormality in mice that were haploinsufficient for both fibrillin 1 and β1 integrin. Collectively, these findings implicate fibrillin 1 in the physiological adaptation of cardiac muscle to elevated workload.

Authors

Jason R. Cook, Luca Carta, Ludovic Bénard, Elie R. Chemaly, Emily Chiu, Satish K. Rao, Thomas G. Hampton, Peter Yurchenco, Kevin D. Costa, Roger J. Hajjar, Francesco Ramirez

×

Figure 5

Integrin involvement in MFS-related DCM.

Options: View larger image (or click on image) Download as PowerPoint
Integrin involvement in MFS-related DCM.
(A) Illustrative immunoblots of...
(A) Illustrative immunoblots of pFAK and FAK proteins and β1 integrin in myocardial extracts from 3-month-old Fbn1+/+ and Fbn1mgR/mgR mice. Ponceau staining is shown below each immunoblot as an indication of total protein loading. (B) Cardiac function in 3-month-old mice of the indicated genotypes (cHI denotes compound haploinsufficient Fbn1+/–;Itgb1+/– mice), with the representative hearts shown below the assays. *P < 0.05 relative to Fbn1+/+ samples (n = 5 per genotype), and mean ± SD. ANOVA P < 0.05. Scale bar: 5 mm. (C) Illustrative immunoblots of FAK and ERK1/2 proteins in myocardial extracts from 3-month-old Fbn1+/+ and cHI mice (n = 5). In A and C, numbers above each lane indicate ratios between phosphorylated and nonphosphorylated proteins. FAK immunoblot in C includes lanes that were run on the same gel but were not contiguous.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts